Vascular Endothelial Growth Factor A
"Vascular Endothelial Growth Factor A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced.
Descriptor ID |
D042461
|
MeSH Number(s) |
D12.644.276.100.800.200 D12.776.467.100.800.200 D23.529.100.800.200
|
Concept/Terms |
Vascular Endothelial Growth Factor A- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factor-A
- VEGF-A
- Vasculotropin
- VEGF
- Vascular Endothelial Growth Factor
- Vascular Permeability Factor
- Permeability Factor, Vascular
|
Below are MeSH descriptors whose meaning is more general than "Vascular Endothelial Growth Factor A".
Below are MeSH descriptors whose meaning is more specific than "Vascular Endothelial Growth Factor A".
This graph shows the total number of publications written about "Vascular Endothelial Growth Factor A" by people in this website by year, and whether "Vascular Endothelial Growth Factor A" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 3 | 3 |
1997 | 0 | 5 | 5 |
1998 | 0 | 9 | 9 |
1999 | 0 | 16 | 16 |
2000 | 0 | 26 | 26 |
2001 | 0 | 27 | 27 |
2002 | 0 | 28 | 28 |
2003 | 5 | 34 | 39 |
2004 | 25 | 24 | 49 |
2005 | 22 | 30 | 52 |
2006 | 16 | 23 | 39 |
2007 | 20 | 31 | 51 |
2008 | 23 | 31 | 54 |
2009 | 21 | 38 | 59 |
2010 | 20 | 22 | 42 |
2011 | 21 | 26 | 47 |
2012 | 14 | 20 | 34 |
2013 | 20 | 17 | 37 |
2014 | 16 | 23 | 39 |
2015 | 12 | 24 | 36 |
2016 | 8 | 16 | 24 |
2017 | 10 | 18 | 28 |
2018 | 7 | 12 | 19 |
2019 | 8 | 21 | 29 |
2020 | 2 | 19 | 21 |
2021 | 5 | 21 | 26 |
2022 | 2 | 22 | 24 |
2023 | 6 | 24 | 30 |
2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vascular Endothelial Growth Factor A" by people in Profiles.
-
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid. 2024 Mar; 34(3):347-359.
-
Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration. JCI Insight. 2024 Jan 09; 9(1).
-
A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including central nervous system tumors. Pediatr Blood Cancer. 2024 Mar; 71(3):e30817.
-
Treatment Options for Diabetic Macular Edema. Int Ophthalmol Clin. 2024 Jan 01; 64(1):57-69.
-
Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial. JAMA Ophthalmol. 2023 Dec 01; 141(12):1152-1160.
-
Protective effects of macrophage-specific integrin a5 in myocardial infarction are associated with accentuated angiogenesis. Nat Commun. 2023 Nov 20; 14(1):7555.
-
Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review. Cancer Treat Rev. 2024 Jan; 122:102652.
-
Optimizing Visual Outcomes in Patients With Neovascular Age-Related Macular Degeneration: the Potential Value of Sustained Anti-VEGF Therapy. Ophthalmic Surg Lasers Imaging Retina. 2023 Nov; 54(11):654-659.
-
Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study. ESMO Open. 2023 Dec; 8(6):101609.
-
Subventricular zone cytogenesis provides trophic support for neural repair in a mouse model of stroke. Nat Commun. 2023 10 10; 14(1):6341.